Diagnostics & Research · CAMBRIDGE, MA, United States
$16.44
-0.90% (-$0.15)2026-07-09
Smart-Money SignalNeutral · 50/100— Insiders are net sellers over 90 days (-$129K, 2 sales vs 2 buys)
Revenue$15.0M
Net Income-$96.2M
EPS$-0.81
Market Cap$2.0B
Price Performance
Historical data including institutional events
Company Profile
J
John Leonard
CEO & Executive Director
Intellia Therapeutics, Inc. is an American clinical-stage biotechnology company focused on developing novel, potentially curative therapeutics leveraging CRISPR-based technologies. The company's in vivo programs use intravenously administered CRISPR as the therapy, in which the company's proprietary delivery technology enables highly precise editing of disease-causing genes directly within specific target tissues. Intellia's ex vivo programs use CRISPR to create the therapy by using engineered human cells to treat cancer and autoimmune diseases.
